-
Your selected country is
France
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD OptEIA™ Monkey IFN-γ ELISA Set
(RUO)This standard curve is fordemonstration only. A standard curve must be run with each assay. \"Typical Standard Curve\" and 20-plate yield were obtained in the BD Biosciences Pharmingen laboratory, using the recommended procedure and manual plate washing.
BD OptEIA™ Monkey IFN-γ ELISA Set
BD OptEIA™ Monkey IFN-γ ELISA Set
Monkey IFN-γ ELISA Set
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Description
The OptEIA™ Set for monkey interferon- gamma (IFN-γ) contains the components necessary to develop enzyme-linked immunosorbent assays (ELISA) for natural or recombinant IFN-γ in non-human primate (rhesus, cynomolgus, and baboon) serum, plasma, and cell culture supernatants. Sufficient materials are provided to yield approximately 20 plates of 96-wells if the recommended storage, materials, buffer preparation, and assay procedure are followed as specified in this package.
Assay Optimization
BD OptEIA™ Sets allow flexible assay design to fit individual laboratory needs. To design an immunoassay with different sensitivity and dynamic range, the following parameters can be varied: Capture, Detection Antibody titers, Incubation time, Incubation temperature, Assay Diluent formulation, Buffer pH, ionic strength, protein concentration, Type of substrate, Washing technique (i.e., number of wash repetitions and soak times)
Standardization: The standard in this Set is calibrated against purified Baculovirusexpressed recombinant human IFN-γ. In this BD OptEIA™ Set, one monkey IFN-γ unit (U) is defined as one picogram of recombinant human IFN-γ.
Preparation And Storage
Recommended Assay Procedures
Recommended buffers, solutions
Note: Do not use sodium azide in these preparations. Sodium azide inactivates thehorseradish peroxidase enzyme.
The BD OptEIA™ Reagent Set B (Cat. No 550534) containing Coating Buffer, Assay Diluent, Substrate Reagents A and B, Stop Solution and 20X Wash Buffer Concentrate is recommended.
1. Coating Buffer - 0.1 M Sodium Carbonate, pH 9.5; 7.13 g NaHCO3, 1.59 g Na2CO3; q.s. to 1.0 L; pH to 9.5 with 10 N NaOH. Freshly prepare or use within 7 days of preparation, stored at 2-8°C.
2. Assay Diluent- PBS* with 10% FBS#, pH 7.0. The BD Pharmingen™ Assay Diluent (Cat. No. 555213) is recommended.
*Phosphate-Buffered Saline: 80.0 g NaCl. 11.6 g Na2HPO4, 2.0 g KH2PO4, 2.0 g KCL, q.s. to 10 L; pH to 7.0.
#Fetal Bovine Serum: Hyclone Cat. No. SH30088 (heatinactivated) recommended.
Freshly prepare or use within 3 days of preparation, with 2-8°C storage.
3. Wash Buffer - PBS* with 0.05% Tween-20. Freshly prepare or use within 3 days of preparation, stored at 2-8°C.
4. Substrate Solution - Tetramethylbenzidine (TMB) and Hydrogen Peroxide. The BD Pharmingen™ TMB Substrate Reagent Set (Cat. No. 555214) is recommended.
5. Stop Solution - 1 M H3PO4 or 2 N H2SO4
Additional Materials Required
1. 96-well BD Falcon™ ELISA plates (Cat. No. 353279) are recommended
2. Microplate reader capable of measuring absorbance at 450 nm
3. Precision pipettes
4. Graduated cylinder, one liter
5. Deionized or distilled water
6. Wash bottle or automated washer
7. Log-log graph paper or automated data reduction
8. Tubes to prepare standard dilutions
9. Laboratory timer
10. Plate sealers or parafilm
Specimen Collection and Handling
Specimens should be clear, non-hemolyzed and non-lipemic.
Cell culture supernatants: Remove any particulate material by centrifugation and assay immediately or store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles.
Serum: Use a serum separator tube and allow samples to clot for 30 minutes, then centrifuge for 10 minutes at 1000 x g. Remove serum and assay immediately or store samples at ≤ -20° C. Avoid repeated freeze-thaw cycles.
Plasma: Collect plasma using citrate, EDTA, or heparin as anticoagulant. Centrifuge for 10 minutes at 1000 x g within 30 minutes of collection. Assay immediately or store samples at ≤ -20° C. Avoid repeated freeze-thaw cycles.
Standards Preparation and Handling
1. Reconstitution: After warming lyophilized standard to room temperature, carefully open vial to avoid loss of material. Reconstitute lyophilized standard with 1.0 mL of deionized water to yield a stock standard. Allow the standard to equilibrate for at least 15 minutes before making dilutions. Vortex gently to mix.
2. Storage/ handling of reconstituted standard: After reconstitution, immediately aliquot standard stock in polypropylene vials at 50 μl per vial and freeze at -80°C for up to 6 months. If necessary, store at 2-8° C for up to 8 hours prior to aliquotting/freezing. Do not leave reconstituted standard at room temperature.
3. Standards Preparation for Assay:
a. Prepare a 1000 U/mL standard from the stock standard. Vortex to mix. (See dilution instructions on Instruction/Analysis Certificate.)
b. Add 300 μL Assay Diluent to 6 tubes. Label as 500 U/mL, 250 U/mL, 125 U/mL, 62.5 U/mL, 31.3 U/mL, and 15.6 U/mL.
c. Perform serial dilutions by adding 300 μL of each standard to the next tube and vortexing between each transfer. Assay Diluent serves as the zero standard (0 U/mL).
Working Detector Preparation
(Note: One-step incubation of Biotin/Streptavidin reagents.) Add required volume of Detection Antibody to Assay Diluent. Within 15 minutes prior to use, add required quantity of Enzyme Reagent, vortex or mix well. For recommended dilutions, see lot-specific Instruction/Analysis Certificate. For a full 96-well plate, prepare 12 mL of Working Detector. Discard any remaining Working Detector after use.
Warnings and Precautions
1. Reagents which contain preservatives may be toxic if ingested, inhaled, or in contact with skin.
2. Handle all serum and plasma specimens in accordance with NCCLS guidelines for preventing transmission of blood-borne infections.
3. Capture Antibody contains < 0.1% sodium azide. Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Detection Antibody contains 1% BSA and ProClin™-150 as a preservative
5. Enzyme Reagent contains 1% BSA and ProClin™-300 as preservative
6. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
Recommended Assay Procedure
1. Coat microwells with 100 μL per well of Capture Antibody diluted in Coating Buffer. For recommended antibody coating dilution, see lot-specific Instruction/Analysis Certificate. Seal plate and incubate overnight at 4° C.
2. Aspirate wells and wash 3 times with ≥ 300 μL/well Wash Buffer. After last wash, invert plate and blot on absorbent paper to remove any residual buffer.
3. Block plates with ≥ 200 μL/well Assay Diluent. Incubate at RT for 1 hour.
4. Aspirate/wash as in step 2.
5. Prepare standard and sample dilutions in Assay Diluent. See "Standards Preparation and Handling".
6. Pipette 100 μL of each standard, sample, and control into appropriate wells. Seal plate and incubate for 2 hours at RT.
7. Aspirate/ wash as in step 2, but with 5 total washes.
8. Add 100 μL of Working Detector (Detection Antibody + SAv-HRP reagent) to each well. Seal plate and incubate for 1 hour at RT.
9. Aspirate/ wash as in step 2, but with 7 total washes. NOTE: In this final wash step, soak wells in wash buffer for 30 seconds to 1 minute for each wash.
10. Add 100 μL of Substrate Solution to each well. Incubate plate (without plate sealer) for 30 minutes at room temperature in the dark.
11. Add 50 μL of Stop Solution to each well.
12. Read absorbance at 450 nm within 30 minutes of stopping reaction. If wavelength correction is available, subtract absorbance at 570 nm from absorbance 450 nm.
Assay Procedure Summary
1. Add 100 μL diluted Capture Ab to each well. Incubate overnight at 4° C
2. Aspirate and wash 3 times.
3. Block plates: 200 μL Assay Diluent to each well. Incubate 1 hr RT
4. Aspirate and wash 3 times.
5. Add 100 μL standard or sample to each well. Incubate 2 hr RT.
6. Aspirate and wash 5 times.
7. Add 100 μL Working Detector (Detection Ab + SAv-HRP) to each well. Incubate 1 hr RT
8. Aspirate and wash 7 times (with 30 sec to 1 min soaks)
9. Add 100 μL Substrate Solution to each well. Incubate 30 min RT in dark
10. Add 50 μL Stop Solution to each well. Read at 450 nm within 30 min with λ correction 570 nm.
Calculation of Results
Calculate the mean absorbance for each set of duplicate standards, controls and samples. Subtract the mean zero standard absorbance from each.
Plot the standard curve on log-log graph paper, with IFN-γ concentration on the x-axis and absorbance on the y-axis. Draw the best fit curve through the standard points.
To determine the IFN-γ concentration of the unknowns, find the unknown's mean absorbance value on the y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the x-axis and read the IFN-γ concentration. If samples were diluted, multiply the IFN-γ concentration by the dilution factor.
Computer data reduction may also be employed, utilizing log-log regression analysis.
Specificity
Cross Reactivity: The following factors were tested in the BD OptEIA™ assay at ≥ 100 ng/mL and no cross-reactivity was identified.
Recombinant Human: IL-1α, IL-1β, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, TNF, LT-α (TNF-β), MCP-3, sICAM-1, sCD4, sCD14, sCD25, RANTES, TGF-β, TNFRI, VEGF, IL-4R, IP-10, GRO-α
Product Notices
- For online training for BD OptEIA™ Set ELISA Techniques, please refer to http://www.bdbiosciences.com/OptEIA/downloads.shtml
- Samples that generate absorbance values higher than the standard curve should be diluted with Standard Diluent and re-assayed.
- Interference by drug metabolites, soluble receptors, or other binding proteins in specimens has not been thoroughly investigated. The possibility of interference cannot be excluded.
- BD OptEIA™ Sets are intended for use as an integral unit. Do not mix reagents from different Set batches. Reagents from other manufacturers are not recommended for use in this Set.
- Reagents which contain preservatives may be toxic if ingested, inhaled, or in contact with skin.
- Handle all serum and plasma specimens in accordance with NCCLS guidelines for preventing transmission of blood-borne infections.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- ProClin is a trademark of Rohm and Haas Company.
Description | Quantity/Size | Part Number | EntrezGene ID |
---|---|---|---|
Capture Antibody Purified Anti-Monkey IFN-γ | N/A | 51-27501E | 3458 |
Recombinant IFN-γ Lyophilized Standard | N/A | 51-27506E | 3458 |
Detection Antibody Biotin Anti-Monkey IFN-γ | N/A | 51-27502E | 3458 |
Enzyme Reagent Streptavidin-horseradish peroxidase conjugate (SAv-HRP) | N/A | 51-9002813 | N/A |
Development References (20)
-
Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992; 127:5-24. (Biology). View Reference
-
Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods. 1988; 110(1):29-36. (Biology). View Reference
-
Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983; 65(1-2):109-121. (Biology). View Reference
-
Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993; 11:571-611. (Biology). View Reference
-
Favre C, Wijdenes J, Cabrillat H, Djossou O, Banchereau J, de Vries JE. Epitope mapping of recombinant human gamma interferon using monoclonal antibodies. Mol Immunol. 1989; 26(1):17-25. (Biology). View Reference
-
Fujihashi K, McGhee JR, Beagley KW, et al. Cytokine-specific ELISPOT assay. Single cell analysis of IL-2, IL-4 and IL-6 producing cells. J Immunol Methods. 1993; 160(2):181-189. (Biology). View Reference
-
Green JA, Yeh TJ, Overall JC. Rapid, quantitative, semiautomated assay for virus-induced and immune human interferons. J Clin Microbiol. 1980; 12(3):433-438. (Biology). View Reference
-
Helms T, Boehm BO, Asaad RJ, Trezza RP, Lehmann PV, Tary-Lehmann M. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol. 2000; 164(7):3723-3732. (Biology). View Reference
-
Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981; 75(5):734-738. (Biology). View Reference
-
Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-580. (Biology). View Reference
-
Meager A, Parti S, Barwick S, Spragg J, O'Hagan K. Detection of hybridomas secreting monoclonal antibodies to human gamma interferon using a rapid screening technique and specificity of certain monoclonal antibodies to gamma interferon. J Interferon Res. 1984; 4(4):619-625. (Biology). View Reference
-
Meager A. Characterization of interferons and immunoassays. In: Clemens MJ, Morris AG, Gearing AJH, ed. Lymphokines and Interferons. A Practical Approach. Oxford: IRL Press Ltd; 1987:105-127.
-
Ronnblom L, Cederblad B, Sandberg K, Alm GV. Determination of herpes simplex virus-induced alpha interferon-secreting human blood leucocytes by a filter immuno-plaque assay. Scand J Immunol. 1988; 27(2):165-170. (Biology). View Reference
-
Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.. J Immunol. 2000; 165(5):2903-2910. (Biology). View Reference
-
Sedgwick JD, Holt PG. A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. J Immunol Methods. 1983; 57(1-3):301-309. (Biology). View Reference
-
Sester U, Sester M, Hauk M, Kaul H, Köhler H, Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients.. Nephrol Dial Transplant. 2000; 15(8):1217-1223. (Biology). View Reference
-
Sopper S, Stahl-Hennig C, Demuth M, Johnston IC, Dorries R, ter Meulen V. Lymphocyte subsets and expression of differentiation markers in blood and lymphoid organs of rhesus monkeys. Cytometry. 1997; 29(4):351-362. (Biology). View Reference
-
Verdier F, Aujoulat M, Condevaux F, Descotes J. Determination of lymphocyte subsets and cytokine levels in cynomolgus monkeys. Toxicology. 1995; 105(1):81-90. (Biology). View Reference
-
Vogel S, Friedman R, Hogan M. Measurement of antiviral activity induced by interferons a, b, and g.. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, ed. Current Protocols in Immunology. New York: John Wiley & Sons; 2007:6.9.1-6.9.15.
-
Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.. Nat Med. 2001; 7(3):297-303. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.